Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.


Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.


You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences

inqaba biotec acquires the first PacBio Sequel II System in Africa

Monday, April 20, 2020

Deployment expands access to PacBio’s highly accurate long reads on the African continent for a variety of applications, from ethnic-specific reference genomes to COVID-19 research

MENLO PARK, Calif. and PRETORIA, South Africa, April 20, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, and inqaba biotec, the leading commercial DNA sequencing service provider in sub-Saharan Africa, today announced the addition of a PacBio Sequel II System to inqaba biotec’s portfolio of genomics services. Based on the well-established Single Molecule, Real-Time (SMRT®) Sequencing technology, the Sequel II System offers highly accurate long reads, with 15x more data compared with the original Sequel System.

“We are very pleased to make the PacBio Sequel II System available to researchers on the African continent. In addition to its highly accurate HiFi reads, customers can expect drastically reduced project costs and higher throughput,” said Oliver Preisig, PhD, Executive Director of Inqaba Biotechnical Industries. “As Africa’s Genomics Company, we are particularly excited to be surrounded by such a high degree of biodiversity.”

“It is expected that with data from the Sequel II System, we will now be able to generate highly accurate ethnic-specific human genome datasets to further increase our understanding of population genetics and disease response in Africa, which has greater levels of genetic diversity than any other part of the world,” says Raj Ramesar, Professor and Head of the Division of Human Genetics at the University of Cape Town.

The PacBio Sequel II System is capable of comprehensive variant detection, from single base changes to multi-kilobase structural variants, and can be used for a broad range of applications including whole-genome, amplicon, and full-length transcriptome sequencing, as well as epigenetic characterization. With longer HiFi reads and higher throughput, the Sequel II System will allow inqaba biotec to assemble not only human genomes but also those of plants and animals unique to the African continent.

inqaba biotec also anticipates using the Sequel II System to support regional COVID-19 studies. PacBio is partnering with researchers worldwide to develop protocols using HiFi sequencing to investigate the genetics and epidemiology of the novel SARS-CoV-2 coronavirus, which will aid in understanding and managing the spread of COVID-19. PacBio’s highly accurate long-read sequencing technology has already been used to study other infectious viruses including HIV, HCV, HSV and influenza, and inqaba biotec will provide support to African researchers interested in investigating them and the diseases they cause.

“PacBio is proud to partner with inqaba biotec to establish them as our first Sequel II System service provider for the entire African continent,” said Jonas Korlach, PhD, Chief Scientific Officer of Pacific Biosciences. “We are excited to support efforts underway to sequence human genomes and non-human endemic species for diversity research with our highly accurate HiFi sequencing.”

About Inqaba Biotechnical Industries (Pty) Ltd (www.inqababiotec.co.za)
Inqaba Biotechnical Industries (Pty) Ltd, trading as inqaba biotec, is a unique South African Genomics company with a broad footprint in sub-Saharan Africa having offices in Ghana, Kenya, Nigeria, Tanzania and Senegal as well. Established in 2002, it is the leading company in Africa that provides a full range of DNA sequencing and DNA synthesis services. The company also distributes life and molecular diagnostics products from well-known brands.

About Pacific Biosciences
Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.

Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future availability, uses, accuracy, quality or performance of, or benefits of using, our products or technologies, including SMRT Sequencing, the suitability or utility of our methods, products or technologies for particular applications or projects, the expected benefits, or insights to be gained, by research teams who are using our products or technologies to study SARS-CoV-2 or COVID-19, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.


Media: Colin Sanford203.918.4347

Investors: Trevin Rard650.521.8450


Pacific Biosciences logo

Source: Pacific Biosciences of California, Inc.